• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CC-1065对序列特异性DNA烷基化的分子基础。

Molecular basis for sequence-specific DNA alkylation by CC-1065.

作者信息

Hurley L H, Lee C S, McGovren J P, Warpehoski M A, Mitchell M A, Kelly R C, Aristoff P A

机构信息

Division of Medicinal Chemistry, College of Pharmacy, University of Texas, Austin 78712.

出版信息

Biochemistry. 1988 May 17;27(10):3886-92. doi: 10.1021/bi00410a054.

DOI:10.1021/bi00410a054
PMID:3408734
Abstract

CC-1065 is a potent antitumor antibiotic that binds covalently to N3 of adenine in the minor groove of DNA. The CC-1065 molecule is made up of three repeating pyrroloindole subunits, one of which (the left-hand one or A subunit) contains a reactive cyclopropyl function. The drug reacts with adenines in DNA in a highly sequence-specific manner, overlapping four base pairs to the 5'-side of the covalently modified base. Concomitant with CC-1065 covalent binding to DNA is an asymmetric effect on local DNA structure which extends more than one helix turn to the 5'-side of the covalent binding site. The DNA alkylation, sequence specificity, and biological potency of CC-1065 and a select group of trimeric synthetic analogues were evaluated. The results suggest that (a) noncovalent interactions between this series of compounds and DNA do not lead to the formation of complexes stable enough to be detected by footprinting methods, (b) sequence specificity and alkylation intensity can be modulated by the substituents on the nonreactive middle and right-hand segments, and (c) biological potency correlates well with ability to alkylate DNA. In addition, the extent and the sequence specificity of covalent adduct formation between linear DNA fragments and three analogues comprised of the CC-1065 alkylating subunit linked to zero (analogue A), one (analogue AB), or two (analogue ABC) nonreactive indole subunits were compared.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

CC - 1065是一种强效抗肿瘤抗生素,它与DNA小沟中腺嘌呤的N3位共价结合。CC - 1065分子由三个重复的吡咯并吲哚亚基组成,其中一个(左手边的或A亚基)含有一个具有反应活性的环丙基官能团。该药物以高度序列特异性的方式与DNA中的腺嘌呤反应,在共价修饰碱基的5'侧重叠四个碱基对。与CC - 1065与DNA的共价结合同时发生的是对局部DNA结构的不对称影响,这种影响在共价结合位点的5'侧延伸超过一个螺旋圈。对CC - 1065以及一组选定的三聚体合成类似物的DNA烷基化、序列特异性和生物活性进行了评估。结果表明:(a)该系列化合物与DNA之间的非共价相互作用不会导致形成足够稳定以至于能用足迹法检测到的复合物;(b)序列特异性和烷基化强度可通过非反应性中间和右手段上的取代基进行调节;(c)生物活性与烷基化DNA的能力密切相关。此外,还比较了线性DNA片段与由CC - 1065烷基化亚基与零个(类似物A)、一个(类似物AB)或两个(类似物ABC)非反应性吲哚亚基相连组成的三种类似物之间共价加合物形成的程度和序列特异性。(摘要截于250字)

相似文献

1
Molecular basis for sequence-specific DNA alkylation by CC-1065.CC-1065对序列特异性DNA烷基化的分子基础。
Biochemistry. 1988 May 17;27(10):3886-92. doi: 10.1021/bi00410a054.
2
Determination of the structural features of (+)-CC-1065 that are responsible for bending and winding of DNA.确定负责使DNA弯曲和缠绕的(+)-CC-1065的结构特征。
Chem Res Toxicol. 1991 Mar-Apr;4(2):203-13. doi: 10.1021/tx00020a013.
3
Molecular basis for sequence selective DNA alkylation by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity.(+)-和对映体(-)-CC-1065及相关试剂对序列选择性DNA烷基化的分子基础:适应富含腺嘌呤的富AT序列偏移的腺嘌呤N3烷基化选择性的烷基化位点模型。
Bioorg Med Chem. 1994 Feb;2(2):115-35. doi: 10.1016/s0968-0896(00)82007-6.
4
Demonstration of a pronounced effect of noncovalent binding selectivity on the (+)-CC-1065 DNA alkylation and identification of the pharmacophore of the alkylation subunit.非共价结合选择性对(+)-CC-1065 DNA烷基化的显著影响的证明以及烷基化亚基药效团的鉴定。
Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1431-5. doi: 10.1073/pnas.88.4.1431.
5
Demonstration of the asymmetric effect of CC-1065 on local DNA structure using a site-directed adduct in a 117-base-pair fragment from M13mp1.使用来自M13mp1的117个碱基对片段中的位点定向加合物证明CC - 1065对局部DNA结构的不对称效应。
Proc Natl Acad Sci U S A. 1987 Sep;84(18):6412-6. doi: 10.1073/pnas.84.18.6412.
6
Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065.基于CC-1065的合成抗肿瘤药物生物活性及DNA相互作用的立体电子因素
J Med Chem. 1988 Mar;31(3):590-603. doi: 10.1021/jm00398a017.
7
Construction and characterization of a site-directed CC-1065-N3-adenine adduct within a 117 base pair DNA restriction fragment.在一个117个碱基对的DNA限制性片段内构建和表征位点特异性CC - 1065 - N3 -腺嘌呤加合物。
Biochemistry. 1986 Dec 30;25(26):8430-6. doi: 10.1021/bi00374a016.
8
Inhibition of T4 DNA ligase activity by (+)-CC-1065: demonstration of the importance of the stiffening and winding effects of (+)-CC-1065 on DNA.(+)-CC-1065对T4 DNA连接酶活性的抑制作用:证明(+)-CC-1065对DNA的刚性化和缠绕作用的重要性。
Anticancer Drug Des. 1992 Feb;7(1):15-36.
9
Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.含抗肿瘤药物CC - 1065的烷基化环丙基吡咯并吲哚(CPI)亚基的两种吡唑类似物与聚吡咯小沟结合剂的水溶性杂合分子的设计、合成、DNA结合及生物学评价
J Med Chem. 2001 Aug 2;44(16):2536-43. doi: 10.1021/jm0108404.
10
Evidence for a common molecular basis for sequence recognition of N3-guanine and N3-adenine DNA adducts involving the covalent bonding reaction of (+)-CC-1065.关于涉及(+)-CC-1065共价键合反应的N3-鸟嘌呤和N3-腺嘌呤DNA加合物序列识别的共同分子基础的证据。
Arch Pharm Res. 2002 Feb;25(1):11-24. doi: 10.1007/BF02975255.

引用本文的文献

1
40 Years of Duocarmycins: A Graphical Structure/Function Review of Their Chemical Evolution, from SAR to Prodrugs and ADCs.多卡霉素40年:从构效关系到前药及抗体药物偶联物的化学演变的图形化结构/功能综述
JACS Au. 2022 Nov 15;2(12):2636-2644. doi: 10.1021/jacsau.2c00448. eCollection 2022 Dec 26.
2
Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.用于实体瘤靶向治疗的膜联蛋白导向β-葡萄糖醛酸酶
Protein Eng Des Sel. 2017 Feb;30(2):85-94. doi: 10.1093/protein/gzw063. Epub 2016 Dec 15.
3
Synthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]imidazolo[4,5-e]indol-4-one-6-carboxylate (CImI) alkylation subunit.
包含甲基1,2,8,8a-四氢环丙基[c]咪唑并[4,5-e]吲哚-4-酮-6-羧酸酯(CImI)烷基化亚基的多卡霉素SA类似物的合成与评价。
Bioorg Med Chem. 2016 Oct 15;24(20):4779-4786. doi: 10.1016/j.bmc.2016.04.050. Epub 2016 Apr 26.
4
A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.多卡霉素基于CBI类似物的五元内酯前药。
Tetrahedron Lett. 2015 Jun 3;56(23):3101-3104. doi: 10.1016/j.tetlet.2014.11.038.
5
Asymmetric synthesis of a CBI-based cyclic N-acyl O-amino phenol duocarmycin prodrug.一种基于CBI的环状N-酰基O-氨基苯酚多卡霉素前药的不对称合成。
J Org Chem. 2014 Oct 17;79(20):9699-703. doi: 10.1021/jo501839x. Epub 2014 Oct 3.
6
A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.疏水性性质与 DNA 烷化抗肿瘤药物双氰胺类生物活性之间的基本关系:疏水结合驱动键合。
J Med Chem. 2013 Sep 12;56(17):6845-57. doi: 10.1021/jm400665c. Epub 2013 Aug 29.
7
Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.有效环状 N-酰基 O-氨基苯酚双氰胺前药。
J Med Chem. 2013 May 23;56(10):4104-15. doi: 10.1021/jm400413r. Epub 2013 May 10.
8
A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.一种新型、高效的双氰胺氨基甲酸酯前药,无残留副产物释放。
J Med Chem. 2012 Jun 28;55(12):5878-86. doi: 10.1021/jm300330b. Epub 2012 Jun 12.
9
Asymmetric synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI).1,2,9,9a-四氢环丙[c]苯并[e]吲哚-4-酮(CBI)的不对称合成。
J Org Chem. 2011 Jan 21;76(2):583-7. doi: 10.1021/jo102136w. Epub 2010 Dec 30.
10
Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.设计、合成和评价受可调还原激活控制的柔红霉素 O-氨基苯酚前药。
J Med Chem. 2010 Nov 11;53(21):7731-8. doi: 10.1021/jm1010397.